Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax combinations versus venetoclax plus rituximab in relapsed or refractory CLL/SLL
NL-OMON60062Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sonrotoclax, obinutuzumab, rituximab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by BeOne Medicines. Started Jan 2026; status: recruiting.
02
Drugs
sonrotoclaxobinutuzumabrituximabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60062.